SPTX — Seaport Therapeutics, Inc. Common Stock
SPTX dilution and offerings
- Float: 19.8M shares
$19.60-7.11%
Last close: · regular session
Last 36 sessions
Float: 19.8M shares. Latest SEC filing: 8-K on Nov 2, 2026. SPTX closed at $19.60 (-7.11%) on Oct 30, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for SPTX in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 58
- Website: https://www.seaporttx.com
Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects. All therapeutic candidates in development are based on this platform, with research and development activities focused on neuropsychiatric medicines. The company serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors. The company was founded in 2024 and is based in Boston, Massachusetts.
Latest SEC filings for SPTX
Latest SPTX news
- Seaport Therapeutics, Inc. GAAP EPS of -$0.49 beats by $0.09 Read article
- Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress Read article
- PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance Read article
- Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.